342 related articles for article (PubMed ID: 34736865)
1. Analysis of naloxone access and primary medication nonadherence in a community pharmacy setting.
Connolly E; McCall KL; Couture S; Felton M; Piper BJ; Bratberg JP; Tu C
J Am Pharm Assoc (2003); 2022; 62(1):49-54. PubMed ID: 34736865
[TBL] [Abstract][Full Text] [Related]
2. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
[TBL] [Abstract][Full Text] [Related]
3. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
4. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
[TBL] [Abstract][Full Text] [Related]
5. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with naloxone availability and dispensing through Michigan's pharmacy standing order.
Dahlem CH; Myers M; Goldstick J; Stevenson JG; Gray G; Rockhill S; Dora-Laskey A; Kellenberg J; Brummett CM; Kocher KE
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):454-463. PubMed ID: 35405078
[No Abstract] [Full Text] [Related]
8. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
[TBL] [Abstract][Full Text] [Related]
9. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
[TBL] [Abstract][Full Text] [Related]
10. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
[TBL] [Abstract][Full Text] [Related]
12. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
[TBL] [Abstract][Full Text] [Related]
13. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
14. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
[TBL] [Abstract][Full Text] [Related]
15. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy.
Sexton SM; Armstrong A; Gatton O; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2019; 59(4S):S95-S100. PubMed ID: 31231001
[TBL] [Abstract][Full Text] [Related]
16. Association Between a State Law Allowing Pharmacists to Dispense Naloxone Without a Prescription and Naloxone Dispensing Rates.
Gangal NS; Hincapie AL; Jandarov R; Frede SM; Boone JM; MacKinnon NJ; Koechlin K; DeFiore-Hyrmer J; Holthusen A; Heaton PC
JAMA Netw Open; 2020 Jan; 3(1):e1920310. PubMed ID: 32003819
[TBL] [Abstract][Full Text] [Related]
17. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
[TBL] [Abstract][Full Text] [Related]
18. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE
J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151
[TBL] [Abstract][Full Text] [Related]
19. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
20. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
